Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). The MST-16 Study Group.
BACKGROUND
MST-16, a new orally administered bis(2,6-dioxopiperazine) analogue and an inhibitor of topoisomerase II, was given to 24 patients with adult T-cell leukemia-lymphoma (ATLL) in a Phase I-II multi-institutional cooperative study.


METHODS
MST-16 was administered orally daily for 7 days, with courses repeated at intervals of 2-3 weeks in 24 patients.


RESULTS
Two complete remissions (CR) and eight partial remissions (PR) were obtained in 23 evaluable patients who received 1200-2800 mg/day of MST-16. Among 13 acute-type ATLL, one CR and five PR were obtained. Among eight lymphoma-type ATLL, two PR were detected. Among two chronic-type ATLL, one CR and one PR occurred. Remissions were obtained at 7-232 days (median, 23 days) and lasted 43-374 days (median, 68 days). The major toxic effects were leukopenia (68%), anemia (52%), thrombocytopenia (35%), and gastrointestinal disorders (22%).


CONCLUSIONS
MST-16 was shown to be effective in ATLL, which has no standard therapy. This drug deserves further clinical trials because it shows little cross resistance to currently available antitumor drugs.
Ohno
R
R
Department of Medicine, Nagoya University School of Medicine, Japan.
Masaoka
T
T
Shirakawa
S
S
Sakamoto
S
S
Hirano
M
M
Hanada
S
S
Yasunaga
K
K
Yokomaku
S
S
Mitomo
Y
Y
Nagai
K
K
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002415:Cats; D005260:Female; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D010879:Piperazines; D059005:Topoisomerase II Inhibitors; C057773:sobuzoxane